Recent progress in vaccine development against Leishmania species infections

Canadian Journal of Infectious Diseases

Volumn 10, Issue SUPPL. 3, 1999, Pages

  Papadopoulou, Barbara ^a,b   Olivier, Martin ^a   Ouellette, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Leishmania; T cell mediated immunity; Vaccine development

Indexed keywords

EID: 4244067756     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/168108     Document Type: Article

References (93)

1. Ashford RW, Desjeux P, deRaadt P. Estimation of population at risk of Infection and number of cases of leishmaniasis. Parasitol Today 1992;8:104-5.
2. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 1995;89(Suppl 1):83-8.
3. Magill AJ, Grogl M, Gasser RA Jr, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993;328:1383-7.
4. Ouellette M, Papadopoulou B. Mechanisms of drug resistance in leishmania. Parasitol Today 1993;9:150-3.
5. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-319.
6. Mosser DM, Rosenthal LA. Leishmania-macrophage interactions: multiple receptors, multiple ligands and diverse cellular responses. Semin Cell Biol 1993;4:315-22.
7. Guy RA, Belosevic M. Comparison of receptors required for entry of Leishmania major amastigotes into macrophages. Infect Immun 1993;61:1553-8.
8. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-77.
9. Lang T, de Chastellier C, Frehel C. Distribution of MHC class I and of MHC class II molecules in macrophages infected with Leishmania amazonensis. J Cell Sci 1994;107:69-82.
10. Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD. Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection. Res Immunol 1991;142:28-32.
11. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993;5:524-31.
12. Heinzel FP, Rerko RM, Hatam F, Locksley RM. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 1993;150:3924-31.
13. Assreuy J, Cunha FQ, Epperlein M, et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994;24:672-6.
14. Wang ZE, Zheng S, Corry DB, et al. Interferon gamma-independent effects of interleukin-12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994;91:12932-6.
15. Swihart K, Fruth U, Messmer N, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med 1995;181:961-71.
16. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin-12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993;90:10188-92.
17. Scharton-Kersten T, Scott P. The role of the innate immune response in Th1 cell development following Leishmania major infection. J Leukoc Biol 1995;57:515-22.
18. Heinzel FP, Rerko RM, Ahmed F, Pearlman E. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995;155:730-9.
19. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN-gamma production and type 1 cytokine responses. Immunity 1996;4:471-81.
20. Ohmori Y, Hamilton TA. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J Immunol 1997;159:5474-82.
21. Ho JL, Reed SG, Wick EA, Giordano M. Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis. J Infect Dis 1990;162:224-30.
22. Liew FY, Li Y, Yang DM, Severn A, Cox FE. TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis. Immunology 1991;74:304-9.
23. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin-12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
24. Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995;181:387-91.
25. Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest 1995;95:1183-92.
26. Hondowicz BD, Scharton-Kersten TM, Jones DE, Scott P. Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response. J Immunol 1997;159:5024-31.
27. Ghalib HW, Whittle JA, Kubin M, et al. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 1995;154:4623-9.
28. Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-77.
29. Shu U, Kiniwa M, Wu CY, et al. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur J Immunol 1995;25:1125-8.
30. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-9.
31. Kamanaka M, Yu P, Yasui T, et al. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 1996;4:275-81.
32. Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996;156:8-11.
33. Muller I, Pedrazzini T, Kropf P, Louis J, Milon G. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol 1991;3:587-97.
34. Muller I, Kropf P, Etges RJ, Louis JA. Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun 1993;61:3730-8.
35. Huber M, Timms E, Mak TW, Rollinghoff M, Lohoff M. Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun 1998;66:3968-70.
36. Sjolander A, Baldwin TM, Curtis JM, Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 1998;160:3949-57.
37. Handman E, Mitchell GF. Immunization with leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci USA 1985;82:5910-4.
38. Scott P, Pearce E, Natovitz P, Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J Immunol 1987;139:3118-25.
39. Gorczynski RM. Altered virulence and vaccination properties of Leishmania parasites grown in infected vaccinated mice. Infect Immun 1989;57:2430-3.
40. Nascimento E, Mayrink W, da Costa CA, et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun 1990;58:2198-203.
41. Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998;177:1352-7.
42. Sharifi I, Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Kamesipour A. Cutaneous leishmaniasis in primary school children in the south-eastern Iranian city of Bam, 1994-95. Bull World Health Organ 1998;76:289-93.
43. Bretscher PA, Wei G, Menon JN, Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 1992;257:539-42.
44. Menon JN, Bretscher PA. Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite. Eur J Immunol 1998;28:4020-8.
45. Muyombwe A, Olivier M, Harvie P, Bergeron MG, Ouellette M, Papadopoulou B. Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene. J Infect Dis 1998;177:188-95.
46. Button LL, McMaster WR. Molecular cloning of the major surface antigen of leishmania. J Exp Med 1988;167:724-9.
47. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella Cyphimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990;145:2281-5.
48. McSorley SJ, Xu D, Liew FY. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect Immun 1997;65:171-8.
49. Mougneau E, Altare F, Wakil AE, et al. Expression cloning of a protective Leishmania antigen. Science 1995;268:563-6.
50. Melby PC, Sacks DL. Identification of antigens recognized by T cells in human leishmaniasis: analysis of T-cell clones by immunoblotting. Infect Immun 1989;57:2971-6.
51. Playfair JH, Blackwell JM, Miller HR. Modern vaccines. Parasitic diseases. Lancet 1990;335:1263-6.
52. Soong L, Duboise SM, Kima P, McMahon-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995;63:3559-66.
53. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L major. Immunology 1995;84:173-6.
54. Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994;91:9866-70.
55. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996;2:888-92.
56. Gurunathan S, Sacks DL, Brown DR, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997;186:1137-47.
57. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995;92:10267-71.
58. Hubel A, Krobitsch S, Horauf A, Clos J. Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite. Mol Cell Biol 1997;17:5987-95.
59. Mottram JC, McCready BP, Brown KG, Grant KM. Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of Leishmania mexicana. Mol Microbiol 1996;22:573-83.
60. Mottram JC, Souza AE, Hutchison JE, Carter R, Frame MJ, Coombs GH. Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci USA 1996;93:6008-13.
61. Zhang WW, Matlashewski G. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. Proc Natl Acad Sci USA 1997;94:8807-11.
62. Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the kinetoplastida. Annu Rev Microbiol 1992;46:695-729.
63. Dumas C, Ouellette M, Tovar J, et al. Disruption of the trypanothione reductase gene of leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 1997;16:2590-8.
64. Cruz AK, Titus R, Beverley SM. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc Natl Acad Sci USA 1993;90:1599-603.
65. Tovar J, Cunningham ML, Smith AC, Croft SL, Fairlamb AH. Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. Proc Natl Acad Sci USA 1998;95:5311-6.
66. Gruber WC, Belshe RB, King JC, et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis 1996;173:1313-9.
67. Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis 1996;174(Suppl 3):S324-9.
68. Coster TS, Killeen KP, Waldor MK, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995;345:949-52.
69. Kotloff KL, Noriega F, Losonsky GA, et al. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun 1996;64:4542-8.
70. Guerin N, Teulieres L, Noba A, Schlumberger M, Bregere P, Chauvin P. Comparison of the safety and immunogenicity of the lyophilized Merieux seed and the World Health Organization working reference BCG vaccines in school-aged children in Senegal. Vaccine 1999;17:105-9.
71. Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR Jr, Bloom BR. Auxotrophic vaccines for tuberculosis. Nat Med 1996;2:334-7.
72. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994;263:235-7.
73. Maingon R, LeRay D, Hommel M. Leishmaniasis research and the European Union. Parasitol Today 1995;11:357-9.
74. Castes M, Blackwell J, Trujillo D, et al. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. 1: Skin-test reactivity, T-cell proliferation and interferon-gamma production. Vaccine 1994;12:1041-51.
75. Fortier AH, Mock BA, Meltzer MS, Nacy CA. Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice. Infect Immun 1987;55:1707-14.
76. Wilson ME, Young BM, Andersen KP. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 1995;63:2062-9.
77. Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 1988;140:1274-9.
78. Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization. J Immunol 1989;142:4441-9.
79. Scott P, Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin Immunol 1997;9:285-91.
80. Frankenburg S, Axelrod O, Kutner S, et al. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine 1996;14:923-9.
81. Ferlin WG, von der Weid T, Cottrez F, Ferrick DA, Coffman RL, Howard MC. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur J Immunol 1998;28:525-31.
82. Gonzalez CR, Noriega FR, Huerta S, et al. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 1998;16:1043-52.
83. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995;63:4261-7.
84. Webb JR, Campos-Neto A, Ovendale PJ, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998;66:3279-89.
85. Walker PS, Scharton-Kersten T, Rowton ED, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998;9:1899-907.
86. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998;4:1409-15.
87. Xu D, McSorley SJ, Chatfield SN, Dougan G, Liew FY. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (AroA-AroD-). Immunology 1995;85:1-7.
88. Soo SS, Villarreal-Ramos B, Anjam Khan CM, Hormaeche CE, Blackwell JM. Genetic control of immune response to recombinant antigens carried by an attenuated Salmonella typhimurium vaccine strain: Nramp1 influences T-helper subset responses and protection against leishmanial challenge. Infect Immun 1998;66:1910-7.
89. Xu D, McSorley SJ, Tetley L, et al. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium. J Immunol 1998;160:1285-9.
90. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the leishmania surface proteinase gp63. Proc Natl Acad Sci USA 1993;90:11473-7.
91. Abdelhak S, Louzir H, Timm J, et al. Recombinant BCG expressing the leishmania surface antigen gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 1995;141:1585-92.
92. McMahon-Pratt D, Rodriguez D, Rodriguez JR, et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun1993;61:3351-9.
93. Tovar J, Wilkinson S, Mottram JC, Fairlamb AH. Evidence that trypanothione reductase is an essential enzyme in Leishmania by targeted replacement of the tryA gene locus. Mol Microbiol 1998;29:653-60.